Wikisage, the free encyclopedia of the second generation, is digital heritage
Brivaracetam: Difference between revisions
Jump to navigation
Jump to search
m (atc) |
m (neuropsi dis treat) |
||
Line 2: | Line 2: | ||
4n propyl analog of [[levetiracetam]], this a levetiracetam may have potential in the mangement of progressive myoclonic [[epilepsy|epilepsies]] | 4n propyl analog of [[levetiracetam]], this a levetiracetam may have potential in the mangement of progressive myoclonic [[epilepsy|epilepsies]] | ||
<ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670022/pdf/ndt-11-2967.pdf</ref> | <ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670022/pdf/ndt-11-2967.pdf Profile of brivaracetam and its potential in the treatment of epilepsy]</ref> | ||
==Links== | ==Links== | ||
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm486827.htm | http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm486827.htm | ||
Line 10: | Line 11: | ||
===ATC=== | ===ATC=== | ||
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | {| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | ||
|colspan=2| <center> | |colspan=2| <center> |
Revision as of 01:26, 30 March 2016
-
(2S)-2-[(4R)-2-oxo- 4-propylpyrrolidin-1-yl] butanamide
4n propyl analog of levetiracetam, this a levetiracetam may have potential in the mangement of progressive myoclonic epilepsies [1]
Links
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm486827.htm
ATC